New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
16:14 EDTZIOPZiopharm initiated with a Neutral at Piper Jaffray
Target $5.
News For ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
11:47 EDTZIOPOptions with increasing implied volatility
Options with increasing implied volatility: ETE WMB ZIOP Z INFN MRO QLIK SHLD SPLK WPZ
February 10, 2016
11:20 EDTZIOPOptions with increasing implied volatility
Options with increasing implied volatility: ZIOP ETE INFN X PSEC PAGP MRO ETP SPLK HCP
February 9, 2016
10:38 EDTZIOPHigh option volume stocks: CTCT WYN DPM MXL CSOD PAGP HDP ZIOP QLYS ADS
Subscribe for More Information
07:10 EDTZIOPZIOPHARM says first patient enrolled in Phase 1 study of CAR T-Cell therapy
ZIOPHARM Oncology (ZIOP) announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells. The Sleeping Beauty transposon-transposase is a unique non-viral system for introducing genes encoding CARs and T-cell receptors into lymphocytes and is exclusively licensed by Intrexon Corporation (XON) through The University of Texas MD Anderson Cancer Center and accessed as part of ZIOPHARM's collaboration.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use